Allergy Testing — Cost, Top Hospitals & Success Rates | MyMedicPlus

Allergy testing is the essential diagnostic step that identifies the specific allergens causing a patient's allergic symptoms, enabling accurate diagnosis, targeted allergen avoidance advice, and — crucially — selection of the correct allergens for immunotherapy treatment. Without objective allergy testing, treatment decisions are based on clinical history alone, which accurately identifies the causative allergen in only 50-60% of cases, leading to inadequate management and potentially inappropriate immunotherapy prescription.

Allergic diseases are defined by their immunological mechanism: IgE-mediated (Type I hypersensitivity) reactions involve allergen-specific IgE antibodies bound to mast cells and basophils, which trigger immediate (within minutes) release of histamine and other mediators on allergen exposure. Testing for IgE-mediated allergy uses skin prick testing or serum specific IgE measurement. Non-IgE-mediated reactions include T cell-mediated contact allergy (Type IV) diagnosed by patch testing, and delayed drug reactions. Mixed or uncertain mechanism reactions — eosinophilic oesophagitis, food protein-induced enterocolitis — require specialist investigation beyond standard IgE allergy testing.

Allergy testing must always be interpreted in the context of the clinical history — a positive test in a patient with no compatible symptoms is clinically meaningless (many people are sensitised but not clinically allergic). Conversely, a negative test in a patient with convincing IgE-mediated symptoms should prompt consideration of alternative diagnoses or referral to a specialist allergy clinic. Over-diagnosis of allergy from untested clinical history or non-evidence-based testing (IgG food panel testing, hair analysis, vega testing, applied kinesiology) is a significant clinical problem causing unnecessary dietary restriction and avoidance with no clinical benefit and potential nutritional harm.

For international patients seeking allergy evaluation, specialist allergy departments at major hospitals in India, Singapore, and Thailand offer comprehensive allergy diagnostic work-up at substantially lower cost than Western allergy clinics.

Allergic rhinitis and allergic rhinoconjunctivitis — seasonal (hay fever) or perennial — is the most common indication for allergy testing to identify the causative aeroallergens (grasses, trees, weeds, house dust mite, pet danders, moulds) and guide environmental control and immunotherapy selection. Allergic asthma evaluation requires identifying which aeroallergens contribute to asthma triggers, informing both avoidance and immunotherapy decisions.

Food allergy testing is performed for patients with suspected IgE-mediated food reactions — urticaria, angioedema, or anaphylaxis within 30-60 minutes of food ingestion. Common food allergens tested include peanut, tree nuts, milk, egg, wheat, soy, fish, and shellfish. Oral food challenge (OFC) remains the definitive diagnostic gold standard for food allergy when skin and blood tests are inconclusive. Drug allergy testing evaluates suspected reactions to antibiotics (penicillin, cephalosporins), NSAIDs, anaesthetic agents, and chemotherapy drugs, using intradermal testing, drug provocation testing, or specific IgE where available. Insect venom allergy evaluation is performed for patients with previous systemic reactions to bee or wasp stings, using venom-specific skin prick test and serum IgE, to confirm venom allergy before prescribing immunotherapy. Occupational allergy investigation identifies workplace allergens in baker's asthma (flour dust), latex allergy in healthcare workers, animal dander in laboratory workers, and isocyanate asthma in paint sprayers.

Allergy testing is indicated for any patient with symptoms suggesting IgE-mediated allergy where the causative allergen is uncertain or requires objective confirmation before initiating treatment or immunotherapy. Clinical indications include: moderate-to-severe allergic rhinitis with unclear allergen(s); suspected food allergy following an immediate reaction; history of anaphylaxis requiring investigation of trigger; consideration for allergen immunotherapy (testing confirms sensitisation and identifies which allergens to include); occupational symptoms suggesting allergic cause; and suspected drug allergy where safer alternatives need to be identified.

Antihistamines (cetirizine, loratadine, fexofenadine) must be stopped for 5-7 days before skin prick testing, as they suppress the skin test wheal response — the length of antihistamine washout depends on the agent's half-life. Long-acting antihistamines (hydroxyzine) require longer washout (up to 10 days). Oral corticosteroids and topical corticosteroids at the test site may also suppress reactions. The patient should not have active severe eczema on the test site (forearm), active urticaria, or have used systemic steroids recently, as these may produce unreliable results.

Skin prick testing (SPT) is the first-line investigation for IgE-mediated aeroallergen and food allergy. Standardised allergen extracts are applied to the volar forearm and the skin is pricked through the drop. At 15-20 minutes, the wheal size (raised area) produced by histamine release from sensitised dermal mast cells is measured. A wheal of 3 mm or more larger than the negative control is considered positive. SPT is fast, cheap, provides immediate results, and has excellent sensitivity and specificity for the most common allergens. It can test 20-30 allergens simultaneously.

Intradermal testing uses a small volume of dilute allergen injected intradermally (within the skin), producing a more sensitive result than SPT and used particularly for drug allergy testing and venom allergy when SPT is equivocal. Serum specific IgE testing (ImmunoCAP, Phadia) measures allergen-specific IgE antibody levels in blood, providing a quantitative result (in kUA/L) correlated with allergy probability. Specific IgE is the preferred test when skin testing is not possible (active eczema, dermographism, patient on antihistamines), and for food allergy where SPT-IgE prediction tables guide clinical decision-making. Component-resolved diagnostics (CRD) tests IgE to specific molecular allergen components (e.g., peanut Ara h 2, hazelnut Cor a 9, birch pollen Bet v 1) providing clinically important information about genuine primary sensitisation versus cross-reactivity and actual anaphylaxis risk. Patch testing for contact allergy (Type IV) applies standardised panels (European Standard Series, metals, fragrances, preservatives, rubber accelerators) to the back under occlusion for 48 hours, with readings at 48 and 96 hours identifying the specific contactants causing allergic contact dermatitis. Oral food challenge (OFC) is the diagnostic gold standard for food allergy — the suspected food is given in increasing doses under medical supervision and the patient is observed for allergic reactions.

Accurate allergy testing enables targeted management that is far superior to empirical avoidance based on untested clinical history. Identifying the specific causative allergen(s) allows precise avoidance advice (avoiding house dust mite rather than all pets, avoiding birch pollen foods rather than all fruits) and selects the correct allergens for immunotherapy — which has no effect unless the patient is sensitised to the allergens included in the extract.

Oral food challenge confirms or refutes food allergy with certainty — avoiding unnecessary dietary restriction in patients who test mildly positive but are not truly allergic (approximately 50% of patients with positive food-specific IgE below 15 kUA/L pass their oral challenge and do not need avoidance). Oral food challenge is also used to document naturally acquired tolerance (as many children with early milk and egg allergy become tolerant by school age) and to expand diet safely. Drug provocation testing and drug allergy delabelling — confirming through graded challenge that a patient labelled as 'penicillin allergic' (often from a childhood rash that was non-IgE-mediated) can in fact safely use penicillin — has major healthcare cost and antimicrobial stewardship benefits: approximately 80-90% of patients labelled penicillin allergic are found to tolerate the drug on challenge.

Skin prick testing and serum specific IgE testing are extremely safe. SPT carries a very small systemic reaction risk of approximately 0.02% per test session — oral antihistamines and rarely adrenaline may be required. The 20-minute observation after SPT session is standard. Intradermal testing carries a higher systemic reaction risk than SPT and should be performed in clinics with emergency resuscitation equipment and at least 30 minutes' observation.

Oral food challenge carries the most significant risk of allergy testing: planned allergen ingestion in a sensitised patient can trigger anaphylaxis in 5-10% of challenges performed in clinical practice. All OFCs are performed in a medical setting with a nurse or doctor present throughout, an intravenous cannula placed, adrenaline immediately available, and standardised stopping rules. Despite these precautions, patient selection (not challenging patients with recent uncontrolled systemic reactions or current asthma exacerbation) is critical to safe OFC practice. Drug provocation testing for suspected beta-lactam allergy is performed with escalating doses under supervision, with the most common adverse event being a mild skin rash occurring in 2-5% of graded challenges.

Allergy test results must always be interpreted by a specialist allergist in the context of the patient's clinical history — test results alone do not make a diagnosis. A positive SPT or specific IgE indicates sensitisation (presence of allergen-specific IgE) but only confirms clinical allergy when combined with compatible symptoms. The 'positive predictive value' varies by allergen: for grass pollen rhinitis, a positive SPT in a patient with seasonal symptoms is highly predictive; for multi-allergen food panels in eczema patients, positive tests frequently represent sensitisation without clinical reactivity.

Component-resolved diagnostic results (Ara h 2 positive for peanut, Cor a 9 positive for hazelnut) provide additional certainty about genuine primary sensitisation and anaphylaxis risk versus cross-reactive sensitisation (frequently food-pollen syndromes producing local oral symptoms without systemic risk). Follow-up allergy testing is appropriate after completing allergen immunotherapy (to document decline in specific IgE and rise in specific IgG4 confirming immunological response) and in children with food allergy (annually to check for acquired tolerance, particularly for milk and egg allergy which frequently resolves with age).

Allergy skin prick testing in the United States costs $200-$800 for a standard panel (20-40 allergens) depending on the number of tests and the facility. Serum specific IgE blood testing (ImmunoCAP) costs $50-$200 per allergen in the US; a comprehensive food and aeroallergen panel can cost $500-$2,000. Oral food challenge in the United States costs $500-$2,000 per session including medical supervision. In the United Kingdom, NHS allergy testing is funded for appropriate referrals to specialist NHS allergy clinics; private allergy testing costs £200-£800.

At specialist allergy departments in India — AIIMS, Apollo, Manipal — comprehensive skin prick testing panels cost $30-$80. Specific IgE (ImmunoCAP) testing costs $20-$60 per allergen. Oral food challenge under medical supervision costs $80-$200 in India. Thailand (Bumrungrad International, Samitivej) charges $50-$150 for SPT panels and $50-$150 for specific IgE per allergen. Patients seeking comprehensive allergy evaluation before planning immunotherapy can have the complete diagnostic work-up in India at a fraction of Western costs.

Multiple non-evidence-based allergy testing methods are commercially marketed, including IgG food intolerance panels (testing IgG antibodies to dozens of foods), hair mineral analysis, vega testing (bioelectrical impedance), applied kinesiology, cytotoxic food testing, and lymphocyte transformation tests for food allergy. None of these tests have clinical validity for diagnosing IgE-mediated allergy — they consistently fail to identify genuinely allergic patients and generate false-positive results leading to unnecessary and potentially harmful dietary restriction without clinical benefit.

Food IgG testing in particular is marketed as identifying 'food intolerances' but IgG antibodies to common foods are a normal immunological finding and do not indicate clinical intolerance or allergy. The British Society for Allergy and Clinical Immunology (BSACI), the American Academy of Allergy, Asthma and Immunology (AAAAI), and the European Academy of Allergy and Clinical Immunology (EAACI) all explicitly advise against these tests. Patients seeking allergy testing should ensure they are attending a doctor-led allergy clinic using evidence-based skin prick testing, serum specific IgE (ImmunoCAP), or oral food challenge for diagnosis.